Beijing Winsunny Pharmaceutical CO.LTD

Fuyuan Pharmaceutical announced that the company has received the drug registration certificate for rivaroxaban orally disintegrating tablets issued by the National Medical Products Administration, with specifications of 15 mg and 10 mg, registered as a Category 3 chemical drug, and deemed to have passed the consistency evaluation. The drug is used to prevent venous thrombosis, treat deep vein thrombosis and pulmonary embolism, reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of recurrence of venous thromboembolism in children and adolescents under 18 years of age weighing 30 kg to 50 kg and above 50 kg. The company's application was accepted in December 2024, with cumulative research and development investment of approximately 7.4967 million yuan.

Fuyuan Pharmaceutical announced that it has received a drug registration certificate from the National Medical Products Administration for bromocriptine mesylate tablets, with a specification of 2.5 mg, classified as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. The drug was developed by Novartis, approved for marketing in the United States in 1978 and in China in 1995, and is indicated for endocrine system and nervous system conditions. The company's application was accepted in October 2024 and recently approved, with cumulative research and development investment of approximately 8.4 million yuan.